Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions
- PMID: 12821205
- DOI: 10.1016/s0376-8716(03)00071-1
Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions
Abstract
Background: Buprenorphine is used in the treatment of opioid dependence. Due to its pharmacology, the transfer from methadone to buprenorphine may precipitate withdrawal symptoms.
Methods: Methadone maintained patients with clinical indicators of stability who were seeking withdrawal from methadone were recruited from three Australian states. Patients on methadone doses between 30 and 40 mg were randomised to transfer to buprenorphine by a fixed dose (transfer at 30 mg methadone) or by a variable dose induction (transfer when 'uncomfortable'). A third group of patients with methadone doses less than 30 mg were transferred to buprenorphine at their entry methadone dose. Fifty-one patients were inducted onto buprenorphine using the same dosing protocol with the first dose of 4 mg buprenorphine. Following stabilisation on buprenorphine, patients gradually reduced the buprenorphine dose to 0 mg. Withdrawal severity and drug use was monitored.
Results: There were no significant difference between the transfer at 30 mg and transfer when 'uncomfortable' dosing protocols in severity of withdrawal on transfer from methadone to buprenorphine. Those on doses less than 30 mg reported significantly less withdrawal discomfort at transfer. All but one patient stabilised on buprenorphine. Thirty-eight of the 51 patients inducted onto buprenorphine reached 0 mg.
Conclusions: Transfer from methadone to buprenorphine can safely occur from doses of around 30 mg of methadone. Buprenorphine dose reductions were well tolerated. Thirty-one percent of patients were not using heroin or methadone at 1-month follow-up.
Similar articles
-
Induction of patients with moderately severe methadone dependence onto buprenorphine.Addict Biol. 2005 Jun;10(2):149-55. doi: 10.1080/13556210500123126. Addict Biol. 2005. PMID: 16191667
-
Rotation from methadone to buprenorphine using a micro-dosing regime in patients with opioid use disorder and serious mental illness: A case series.Drug Alcohol Rev. 2024 Nov;43(7):1829-1834. doi: 10.1111/dar.13885. Epub 2024 Jun 19. Drug Alcohol Rev. 2024. PMID: 38894653
-
Transferring methadone-maintained outpatients to the buprenorphine sublingual tablet: a preliminary study.Am J Addict. 2003 Jul-Sep;12(4):365-74. Am J Addict. 2003. PMID: 14504028 Clinical Trial.
-
Methadone and buprenorphine maintenance therapies for patients with hepatitis C virus infected after intravenous drug use.Acta Gastroenterol Belg. 2005 Jan-Mar;68(1):81-5. Acta Gastroenterol Belg. 2005. PMID: 15832591 Review.
-
Clinical efficacy of buprenorphine: comparisons to methadone and placebo.Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S49-57. doi: 10.1016/s0376-8716(03)00059-0. Drug Alcohol Depend. 2003. PMID: 12738350 Review.
Cited by
-
Low-dose buprenorphine initiation and treatment continuation among hospitalized patients with opioid dependence: A retrospective cohort study.J Subst Use Addict Treat. 2024 Mar;158:209261. doi: 10.1016/j.josat.2023.209261. Epub 2023 Dec 14. J Subst Use Addict Treat. 2024. PMID: 38103838 Free PMC article.
-
Characterizing withdrawal from long-acting injectable buprenorphine: An observational case series.Drug Alcohol Depend Rep. 2025 Apr 5;15:100329. doi: 10.1016/j.dadr.2025.100329. eCollection 2025 Jun. Drug Alcohol Depend Rep. 2025. PMID: 40276009 Free PMC article.
-
Pharmacologic treatments for opioid dependence: detoxification and maintenance options.Dialogues Clin Neurosci. 2007;9(4):455-70. doi: 10.31887/DCNS.2007.9.2/hkleber. Dialogues Clin Neurosci. 2007. PMID: 18286804 Free PMC article. Review.
-
Perioperative Management of Buprenorphine: Solving the Conundrum.Pain Med. 2019 Jul 1;20(7):1395-1408. doi: 10.1093/pm/pny217. Pain Med. 2019. PMID: 30500943 Free PMC article. Review.
-
Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine.J Subst Abuse Treat. 2017 Aug;79:12-19. doi: 10.1016/j.jsat.2017.05.010. Epub 2017 May 16. J Subst Abuse Treat. 2017. PMID: 28673522 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources